Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
JNJ-61393215
Другие языки:

    JNJ-61393215

    Подписчиков: 0, рейтинг: 0
    JNJ-61393215
    JNJ-61393215.svg
    Clinical data
    Other names JNJ-3215
    Routes of
    administration    		 Oral
    Drug class Orexin receptor antagonist
    Identifiers
    • [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
    CAS Number
    PubChem CID
    ChemSpider
    ChEMBL
    Chemical and physical data
    Formula C23H18F4N4O2
    Molar mass 458.417 g·mol−1
    3D model (JSmol)
    • [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
    • InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
    • Key:HUKWIAXQBOHZIX-USKNZQBOSA-N

    JNJ-61393215 is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders. It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA). Preliminary clinical findings suggest that JNJ-61393215 may have anti-panic effects in humans. As of November 2021, JNJ-61393215 is in phase 2 clinical trials for the treatment of major depressive disorder and is in the preclinical stage of development for treatment of panic disorder, while no further development has been reported for treatment of other anxiety disorders. The drug was originated and developed by Janssen Pharmaceuticals.

    See also




    Новое сообщение